Teva Pharmaceutical Industries’ (TEVA) Buy Rating Reaffirmed at HC Wainwright

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $54.00 price target on the stock. HC Wainwright‘s target price indicates a potential upside of 26.72% from the company’s previous close.

Several other research analysts have also recently issued reports on the stock. Zacks Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Oppenheimer increased their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Leerink Partners raised their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Finally, JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $48.31.

View Our Latest Stock Report on TEVA

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $42.61 on Tuesday. Teva Pharmaceutical Industries has a twelve month low of $24.01 and a twelve month high of $44.57. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $49.66 billion, a P/E ratio of 99.10, a PEG ratio of 4.09 and a beta of 0.97. The stock’s 50 day moving average is $40.29 and its 200 day moving average is $35.12.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.78 earnings per share. On average, equities research analysts predict that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard Daniell sold 20,003 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $42.80, for a total transaction of $856,128.40. Following the sale, the executive vice president directly owned 55,755 shares in the company, valued at approximately $2,386,314. The trade was a 26.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 715,945 shares of company stock worth $29,061,351 in the last three months. 0.54% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $33,000. Western Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries in the first quarter worth approximately $43,000. Sunbelt Securities Inc. purchased a new stake in Teva Pharmaceutical Industries in the first quarter worth approximately $45,000. CX Institutional bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $54,000. Finally, EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 64.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after purchasing an additional 647 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Featured Articles

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.